Johnson & Johnson Reports $94.2 Billion in Annual Revenue for 2025, Driven by Strong Performance in Innovative Medicine and MedTech

▲ Source of the article: Eshare Medical Device Hub

▲Please indicate the above source at the beginning of the article when reprinting.

2025 is a very critical year for Johnson & Johnson.

In the past few years, this century-old pharmaceutical giant has faced multiple challenges simultaneously, including patent expirations, the impact of biosimilars, and adjustments to the U.S. healthcare payment system. Market expectations for Johnson & Johnson once shifted from "steady growth" to "defense-oriented."

And from the latest disclosed Q4 and Full-Year 2025 Financial ReportIn view of this, Johnson & Johnson is completing a relatively solid "rebalancing": growth is not aggressive, but the structure has significantly improved, and the quality of profitability is being restored.

First, let's look at the most core overall data:

Q4 2025Johnson & Johnson achieves:

• Revenue of $24.56 billion, year-on-year growth9.1%

• Operational Growth Excluding Currency Impact7.1%

• GAAP Earnings Per Share (EPS) $2.10, year-on-year growth48.9%

• Adjusted EPS $2.46, year-on-year growth20.6%

2025 ChinaCheck it out:

• Annual revenue of $94.2 billion, year-on-year growth6.0%

• Revenue Growth Under Operational Terms5.3%

• GAAP EPS $11.03

• Adjusted EPS $10.79, year-on-year growth8.1%

• Full-year free cash flow of approximately US$19.7 billion

Special attention is required:
The significant growth in GAAP profits was partly driven by tax rates, one-time items, and base effects.What truly reflects operational capability is the approximately 8% growth in adjusted EPS.. This growth rate is already in a relatively favorable range among large global pharmaceutical companies.

From the results, the keyword for Johnson & Johnson in 2025 is not "explosion," butMaintain Stability in a Complex Environment and Gradually Restore Growth Quality。

Johnson & JohnsonThe current business structure can be very clearly divided into two major sectors.

Innovative Medicine

• Total Revenue for 2025: $60.4 billion

• Year-on-year growth6.0%

• Operational Growth5.3%

• Accounting for approximately ___ of the group's total revenueTwo-thirds

Innovative drugs remain the core source of profit and growth for Johnson & Johnson, covering multiple fields such as oncology, immunology, neuroscience, and pulmonary arterial hypertension.

Medical Device (MedTech)

• Full-year revenue for 2025: $33.8 billion

• Year-on-year growth6.1%

• Operational Growth5.4%

• Accounting for approximatelyOne-third

The medical device business includes segments such as cardiovascular, surgical, and vision care, with a relatively stable growth pace but prominent cash flow characteristics.

This combination of "innovative drugs + medical devices" gives Johnson & Johnson a distinct advantage in the pharmaceutical industry:
Able to share in the long-term high-value dividends of innovative drugs, while relying on the medical device business to smooth out cyclical fluctuations.

If we only look at total revenue, the changes at Johnson & Johnson are not drastic; however, from an internal structural perspective, the sources of growth have clearly shifted.

Oncology Business: The Strongest Growth Engine

In the fourth quarter of 2025, Johnson & Johnson's oncology business achieved:

• Revenue of $6.86 billion

• Year-on-year growth24.8%

This is the fastest-growing sector in the entire company.

Core driving forces include:

• DARZALEX: Core product in the multiple myeloma field, with continuous growth

• CARVYKTI：CAR-T Cell Therapy, with Significant Growth as Production Capacity and Treatment Centers Expand

• TECVAYLI、TALVEY: Bispecific products gradually contribute to revenue

• RYBREVANT + LAZCLUZE: Lung cancer combination regimens are in the early stage of increased utilization.

It can be seen that Johnson & Johnson's oncology business is no longer reliant on a single product but has formed a structure with multiple technological pathways and multiple products running in parallel, which significantly enhances long-term stability.

Immune Business: "Structural Shift" in Decline

In contrast to tumors is the immune sector.

• Q4 2025 Immunology Revenue Decreased by 8.9% Year-over-Year

The main reason is very clear:

• Core Old DrugsSTELARAFacing Competition from Biosimilars

• US Medicare Part D Reform Causes Short-Term Impact on Some Products

But at the same time, the new generation of productsTREMFYAOutstanding performance:

• Q4 2025: Year-over-Year Growth of 67.6%

• Continuously expanding market share in fields such as psoriasis and inflammatory bowel disease

This means that the immunization business is not "stalling," but is instead inProduct Transition PhaseFrom the perspective of industry experience, this phase is often the period of greatest short-term pressure.

Neuroscience and Other Fields: Steady Supplementary Growth

Neuroscience Sector Achievements in Q4 2025:

• Revenue increased by 19.1% year-over-year

Among them:

• SPRAVATOContinuous Growth

• CAPLYTA(2025 M&A) Begins to Contribute Revenue

In addition, specialized areas such as pulmonary hypertension maintained low to mid-single-digit growth, jointly providing stable support for the core business.

From a regional perspective, Johnson & Johnson's revenue structure is highly balanced.

The whole year of 2025:

• U.S. Market Revenue $53.75 Billion, year-on-year growth6.9%

• International Market Revenue: $40.44 Billion, year-on-year growth5.0%

Among them:

• The European market is growing rapidly.

• Asia-Pacific, Africa and non-American regions maintain moderate growth

This structure means:
Johnson & Johnson does not overly rely on a single market or a single policy environment., against the backdrop of constantly changing global pharmaceutical regulations and payment systems, demonstrates strong risk resistance.

Overall, Johnson & Johnson's Q4 and full-year 2025 financial report conveys three clear signals.

First, the most difficult phase is passing.
The impact of STELARA will be concentrated in 2025, and the future base pressure will gradually ease.

Second, the growth structure is improving.
Oncology becomes the most important growth engine, with medical devices providing stable cash flow support.

Third, future growth is predictable.
The company provided2026 GuidelinesDisplay:

• Estimated revenue approximately$100.5 billion

• An increase of approximately ___ year-over-year6%–7%

• Adjusted EPS Growth Approximately7%

This means that Johnson & Johnson is not entering a high volatility phase, but rather returning toA mid-single-digit, high-quality growth track。

Conclusion

Johnson & Johnson's 2025 earnings report may not be "dazzling," but it is solid enough.

It showcases a mature medical giant gradually restoring its growth resilience through product mix adjustments and business diversification after experiencing cyclical challenges.

For Long-Term ObservationHealthcareFor people in the industry, this is more like aThe Answer Sheet on "Stability and Patience"。

China Medical Device Industry Data Report(2025 Edition)

‍‍